Nahima Miah
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
-
- Antibiotic Use and Resistance
Papers in
-
- SARS-CoV-2 and COVID-19 Research 2
- Co-authors
- Md. Abdul Hamid (1 shared paper)
- Journals
- The Lancet (6 papers)Zenodo (CERN European Organization for Nuclear Research) (1 paper)
- Partner nations
- AustraliaUnited KingdomIndonesia
In The Last Decade
Nahima Miah
7 papers receiving 1.5k citations
Nahima Miah's Hit Papers
Peers
Comparison fields: 5 of 99
- Infectious Diseases 954
- Applied Microbiology and Biotechnology 50
- Neurology 339
- Internal Medicine 56
- Obstetrics and Gynecology 84
Countries citing papers authored by Nahima Miah
This map shows the geographic impact of Nahima Miah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nahima Miah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nahima Miah more than expected).
Fields of papers citing papers by Nahima Miah
This network shows the impact of papers produced by Nahima Miah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nahima Miah. The network helps show where Nahima Miah may publish in the future.
Co-authors
The 1 scholars most cited alongside Nahima Miah, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 230 |
| 5 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 6 | 2023 | 83 | |
| 7 | 1979 | 1 |
About Nahima Miah
Nahima Miah is a scholar working on Infectious Diseases, Insect Science, Renewable Energy, Sustainability and the Environment, Obstetrics and Gynecology and Anesthesiology and Pain Medicine, having authored 7 papers that have together received 1.6k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (2 papers). The work is most often cited by research in Infectious Diseases (954 citations), Applied Microbiology and Biotechnology (50 citations), Neurology (339 citations), Internal Medicine (56 citations) and Obstetrics and Gynecology (84 citations). Nahima Miah has collaborated with scholars based in Australia, United Kingdom and Indonesia. Frequent co-authors include Md. Abdul Hamid. Their work appears in journals such as The Lancet and Zenodo (CERN European Organization for Nuclear Research).
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.